IQVIA Holdings Inc. Analysts Recommend 'Moderate Buy' Rating

Shares of IQVIA Holdings Inc. (NYSE:IQV) have received an average recommendation of "Moderate Buy" from the nineteen research firms currently tracking the company, according to Marketbeat Ratings. Among these analysts, four have rated the stock as a hold, fourteen have suggested a buy, and one has issued a strong buy recommendation. The consensus 12-month price target for IQVIA stock is approximately $256.50.

Various equity research analysts have recently shared their views on IQV shares. On November 5th, JPMorgan Chase & Co. reduced their price target from $279.00 to $240.00 while maintaining an "overweight" rating for the stock. Similarly, on October 14th, Redburn Atlantic initiated coverage on IQVIA with a "buy" rating and set a price target of $276.00. StockNews.com shifted their rating from "buy" to "hold" on November 28th. Morgan Stanley decreased their target from $280.00 to $265.00 and affirmed an "overweight" rating on November 4th. Lastly, Evercore ISI cut their price target from $270.00 to $265.00, maintaining an "outperform" rating for the company.

IQVIA Stock Performance

As of Friday, shares of NYSE:IQV opened at $202.63. The firm has a 50-day moving average of $215.18 and a 200-day moving average of $225.14. IQVIA's quick ratio stands at 0.81, with a current ratio of 0.81, and a debt-to-equity ratio of 1.76. The company's market capitalization is $36.78 billion, with a price-to-earnings ratio of 26.59 and a price-to-earnings-growth ratio of 2.06. Over the past 52 weeks, IQVIA shares have ranged from a low of $187.62 to a high of $261.73.

Institutional Trading of IQVIA

About IQVIA

IQVIA Holdings Inc. engages in providing advanced analytics, technology solutions, and clinical research services to the life sciences industry across various regions, including the Americas, Europe, Africa, and Asia-Pacific. The company operates through three main segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

IQVIA, stocks, analysts